Provided by Tiger Trade Technology Pte. Ltd.

GlucoTrack, Inc.

2.47
+0.09003.78%
Post-market: 2.470.00000.00%16:04 EDT
Volume:27.30K
Turnover:66.97K
Market Cap:1.97M
PE:-0.01
High:2.55
Open:2.39
Low:2.39
Close:2.38
52wk High:136.29
52wk Low:2.18
Shares:798.40K
Float Shares:759.70K
Volume Ratio:0.13
T/O Rate:3.59%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-180.2807
EPS(LYR):-468.2383
ROE:-620.63%
ROA:-164.45%
PB:-1.13
PE(LYR):-0.01

Loading ...

GlucoTrack's Q1 net loss narrows

Reuters
·
May 15

GlucoTrack Q1 EPS $(2.65) Up From $(40.20) YoY

Benzinga Earnings
·
May 15

GlucoTrack Q1 FY26 net loss narrows to USD 4.33 million

Reuters
·
May 15

GlucoTrack Q1 Net Income USD 4.334 Million

THOMSON REUTERS
·
May 15

GlucoTrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

THOMSON REUTERS
·
May 15

Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

GlobeNewswire
·
May 15

GlucoTrack Inc - Submits Ide Application to FDA for US Clinical Study of Implantable Cbgm Technology - SEC Filing

THOMSON REUTERS
·
May 08

Glucotrack submits IDE application to FDA for US implantable glucose monitor study

Reuters
·
May 08

GlucoTrack Announces Ide Submission for U.S. Clinical Study of Its Novel Implantable Continuous Blood Glucose Monitoring Technology

THOMSON REUTERS
·
May 08

Glucotrack Announces Publication of Peer-Reviewed Study In The Journal of Diabetes Research Demonstrating Long-Term Accuracy and Stability of Continuous Blood Glucose Monitoring Technology

GlobeNewswire
·
Apr 30

GlucoTrack announces publication of peer-reviewed article on glucose sensors

TIPRANKS
·
Apr 21

Glucotrack Announces Publication of Peer-Reviewed Study Supporting Long-Life Sensor Design for Implantable Continuous Blood Glucose Monitoring Technology

GlobeNewswire
·
Apr 21

GlucoTrack issues 895,000 unregistered shares in $600,000 note exchange

Reuters
·
Apr 15

GlucoTrack Q4 EPS $(3.97) Up From $(1.24 thousand) YoY

Benzinga Earnings
·
Mar 31

GlucoTrack FY25 net loss narrows to US$19.4 million; R&D expenses rise to US$9.8 million

Reuters
·
Mar 31

Glucotrack Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

GlobeNewswire
·
Mar 31

Why is Glucotrack Stock (GCTK) Up Nearly 30% Today?

TIPRANKS
·
Mar 27

GlucoTrack to file IDE to FDA for continuous blood glucose monitoring technology

TIPRANKS
·
Mar 27

BRIEF-Glucotrack To File Significant Ide With FDA For Us Clinical Trial In Early Q2 Based On Critical 2025 Milestones

Reuters
·
Mar 27

GlucoTrack files FDA IDE in Q2 2026; first-in-human CBGM study posts 7.7% MARD

Reuters
·
Mar 27